デフォルト表紙
市場調査レポート
商品コード
1087068

カルシフェジオール:市場予測(2022年~2027年)

Calcifediol Market - Forecasts from 2022 to 2027

出版日: | 発行: Knowledge Sourcing Intelligence | ページ情報: 英文 120 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=134.18円
カルシフェジオール:市場予測(2022年~2027年)
出版日: 2022年04月29日
発行: Knowledge Sourcing Intelligence
ページ情報: 英文 120 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 目次
概要

世界のカルシフェジオールの市場規模は、2020年に12億423万3,000米ドルとなり、予測期間中に9.27%のCAGRで拡大し、2027年に22億3,984万1,000米ドルになると予測されています。同市場を牽引する要因には、中国やインドなどの新興国における高度医薬品原料(API)製造への支出の増加や、食生活の変化やペースの速い労働環境の結果として、慢性腎臓病(CKD)の世界の有病率が上昇していることなどが挙げられます。

当レポートでは、カルシフェジオールの世界市場を調査し、市場規模や予測、市場の促進要因および課題、市場動向、セグメント別の市場分析、競合情勢、主要企業のプロファイルなどの体系的な情報を提供しています。

目次

第1章 イントロダクション

  • 市場の定義
  • 市場セグメンテーション

第2章 調査手法

  • 調査データ
  • 仮定

第3章 エグゼクティブサマリー

  • 調査のハイライト

第4章 市場力学

  • 市場促進要因
  • 市場抑制要因
  • ポーターのファイブフォース分析
    • エンドユーザーの交渉力
    • 買い手の交渉力
    • 新規参入者の脅威
    • 代替品の脅威
    • 競争企業間の敵対関係
  • 業界のバリューチェーン分析

第5章 カルシフェジオール市場分析:用途別

  • イントロダクション
  • 乳幼児用医薬品
  • 動物飼料
  • その他

第6章 カルシフェジオール市場分析:地域別

  • イントロダクション
  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 南米
    • ブラジル
    • アルゼンチン
    • その他
  • 欧州
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • その他
  • 中東とアフリカ
    • サウジアラビア
    • イスラエル
    • その他
  • アジア太平洋地域
    • 中国
    • 日本
    • インド
    • 韓国
    • インドネシア
    • タイ
    • 台湾
    • その他

第7章 競合情勢と分析

  • 主要企業と戦略分析
  • 新興企業と市場の有利性
  • 合併、買収、合意、およびコラボレーション
  • ベンダー競争力マトリックス

第8章 企業プロファイル

  • Chemvon Biotechnology Co
  • Cayman Chemicals
  • Haoyuan Chemexpress Co., Ltd
  • Pharmaceutical Research Institute (PRI)
  • BOC Sciences
  • BLDpharm
  • Pharmaffiliates
  • ChemScence
  • ApexBio Technology
目次
Product Code: KSI061614181

The calcifediol market is evaluated at US$1,204.233 million for the year 2020 and is projected to grow at a CAGR of 9.27% to reach a market size of US$2,239.841 million by the year 2027.

Calcifediol monohydrate (25-Hydroxyvitamin D3) is a vitamin D3 analogue created by hydroxylation of vitamin D3 (cholecalciferol) using the enzyme cholecalciferol 25-hydroxylase. Increasing expenditures on advanced pharmaceutical ingredients (API) manufacturing in emerging economies such as China and India is expected to keep the calcifediol monohydrate market growing. Furthermore, the global prevalence of chronic kidney disease (CKD) is increasing as a result of changing dietary patterns and a fast-paced work environment, which is boosting the demand for calcifediol monohydrate-based medications. According to the National Centre for Chronic Disease Prevention and Health Promotion (USA), chronic kidney disease affects about 15% of the population in the United States (CKD).

Additionally, the higher incidence of rickets and brittle bones is predicted to boost this industry's growth. According to the Centers for Disease Control and Prevention, rickets affects 5 out of every 1,000,000 children aged 6 months to 5 years. Also, companies are investing heavily in research and development. Because of the advantageous legislation regulating the manufacture and sale of vitamin D analogues and vitamin D3 APIs, leading manufacturers are locating their manufacturing facilities in Europe.

On the other hand, due to the high concentration and purity of vitamin D, the manufacture of this chemical necessitates the use of technologically advanced machinery and high monetary backup, along with factors affecting regulation and standardisation, which stifle industry growth to some extent.

Animal feed, pharmaceuticals, and others are the three application segments that make up the global calcifediol monohydrate market. The usage of calcifediol monohydrate in personal grooming and nutraceutical applications is covered under the other application areas. Broilers, cattle, breeders, and swine are projected to employ calcifediol monohydrate as an important source for calcium and phosphorus absorption in the body and calcium mobilization in bones in the animal sector. Additionally, it aids in the improvement of immune cells. Because of its widespread use in health supplements, injectables, and capsules, the pharmaceuticals segment is also expected to develop at a high CAGR During the forecast period.

The largest market, Asia Pacific, accounts for a considerable portion of the global calcifediol monohydrate market. Vitamin D deficiency is widespread throughout Asia Pacific, particularly in South - East Asia. Rickets is a disease induced by a deficiency of vitamin D that is particularly frequent in China. Furthermore, increasing income levels and significant consumer demand for nutritious and healthy products are anticipated to provide promising prospects for the expansion and development of the region's functional food and beverage products, resulting in increased consumption of vitamin-infused products and, as a result, market growth. Animal feed accounted for a majority of the calcifediol monohydrate generated in the region. The demand for animal feed is predicted to rise as the region's livestock production grows. Moreover, Europe is the second-largest user of calcifediol monohydrate after the United States. Because of the increased prevalence of kidney illnesses, the region is likely to grow rapidly.

COVID-19 Impact

The COVID-19 outbreak caused a substantially positive effect on the calcifediol market. Increasing evidence suggests that vitamin D plays a preventive role in lowering the risk and severity of respiratory tract infections (RTIs), particularly in the context of influenza and COVID-19. Major clinical findings demonstrate that vitamin D insufficiency has a role in the SARS-CoV-2 acute respiratory distress syndrome (ARDS) and that case fatality rates rise with age and SARS-CoV-2 serum concentrations. A multi-centre observational analysis of 537 COVID-19 patients found that those who received calcifediol had a lower mortality rate during the first 30 days of hospitalisation than those who did not. As a result, the calcifediol market had a significant role to play amid the COVID-19 pandemic.

Recent Development

DSM (Netherlands) and Zhejiang Xinhecheng Co Ltd. (China) inked a contract for the sale and purchase of cholesterol in January 2019. Vitamin D3 is made from cholesterol. This deal assisted the organisation in increasing its total capacity and Vitamin D productivity.

Fermenta Biotech Limited (India) signed a 99-year lease deal with the Gujarat Industrial Development Corporation (GIDC) authority in Ankleshwar, Sayakha in January 2019 to acquire a 40,000-square-meter plot of land for future expansion.

Market Segmentation

  • By Application

Pharmaceutical

Animal feed

Others

  • By Geography

North America

  • USA
  • Canada
  • Mexico

South America

  • Brazil
  • Argentina
  • Others

Europe

  • United Kingdom
  • Germany
  • France
  • Italy
  • Others

Middle East and Africa

  • Saudi Arabia
  • Israel
  • Others

Asia Pacific

  • China
  • Japan
  • India
  • South Korea
  • Indonesia
  • Thailand
  • Taiwan
  • Others

TABLE OF CONTENTS

1. Introduction

  • 1.1. Market Definition
  • 1.2. Market Segmentation

2. Research Methodology

  • 2.1. Research Data
  • 2.2. Assumptions

3. Executive Summary

  • 3.1. Research Highlights

4. Market Dynamics

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porters Five Forces Analysis
    • 4.3.1. Bargaining Power of End-Users
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis

5. Calcifediol Market Analysis, by Application

  • 5.1. Introduction
  • 5.2. Infant Pharmaceuticals
  • 5.3. Animal feed
  • 5.4. Others

6. Calcifediol Market Analysis, by Geography

  • 6.1. Introduction
  • 6.2. North America
    • 6.2.1. USA
    • 6.2.2. Canada
    • 6.2.3. Mexico
  • 6.3. South America
    • 6.3.1. Brazil
    • 6.3.2. Argentina
    • 6.3.3. Others
  • 6.4. Europe
    • 6.4.1. United Kingdom
    • 6.4.2. Germany
    • 6.4.3. France
    • 6.4.4. Italy
    • 6.4.5. Others
  • 6.5. Middle East and Africa
    • 6.5.1. Saudi Arabia
    • 6.5.2. Israel
    • 6.5.3. Others
  • 6.6. Asia Pacific
    • 6.6.1. China
    • 6.6.2. Japan
    • 6.6.3. India
    • 6.6.4. South Korea
    • 6.6.5. Indonesia
    • 6.6.6. Thailand
    • 6.6.7. Taiwan
    • 6.6.8. Others

7. Competitive Environment and Analysis

  • 7.1. Major Players and Strategy Analysis
  • 7.2. Emerging Players and Market Lucrativeness
  • 7.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 7.4. Vendor Competitiveness Matrix

8. Company Profiles 

  • 8.1. Chemvon Biotechnology Co
  • 8.2. Cayman Chemicals
  • 8.3. Haoyuan Chemexpress Co., Ltd
  • 8.4. Pharmaceutical Research Institute (PRI)
  • 8.5. BOC Sciences
  • 8.6. BLDpharm
  • 8.7. Pharmaffiliates
  • 8.8. ChemScence
  • 8.9. ApexBio Technology